Abeona Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed commercial-stage biopharmaceutical company with common stock traded as ABEO. Recent Form 8-K reports cover operating results, ZEVASKYN commercial launch disclosures, completion of the sale of a Rare Pediatric Disease Priority Review Voucher received after FDA approval of ZEVASKYN, and other material events.
Proxy and governance filings describe annual meeting procedures, board composition, committee assignments, director independence, compensation matters, and amendments to the company’s bylaws. Those bylaws disclosures address stockholder meeting mechanics, virtual meetings, proposal and nomination procedures, quorum requirements, and other Delaware corporate governance provisions.
Abeona Therapeutics Inc. director Mark Alvino reported selling 13,500 shares of the company’s common stock on 01/21/2026. The shares were sold at a weighted average price of $5.2277 per share, with individual trade prices ranging from $5.21 to $5.235. After this transaction, he beneficially owns 48,752 common shares directly.
The filing notes that detailed price and size information for each individual trade within the reported price range is available upon request from the company, any security holder, or the SEC staff.
A stockholder has filed a notice of intent to sell 13,500 shares of common stock, with an aggregate market value of $70,574, through broker Stifel Nicolaus & Company Inc. on or around 01/21/2026 on the Nasdaq exchange. These shares were acquired from the issuer on 07/08/2025 as restricted stock units granted as equity compensation, and became payable in shares on the same date.
Over the past three months, the person for whose account the securities are to be sold has already sold 15,000 shares of common stock, generating $71,168 in gross proceeds. By signing the notice, the seller represents that they are not aware of any material adverse, nonpublic information about the issuer’s current or prospective operations.
Abeona Therapeutics reported an insider equity award to its Chief Financial Officer, Joseph Walter Vazzano. On January 20, 2026, he received 133,595 shares of common stock as restricted stock at a price of $0.00 per share, indicating a stock-based compensation grant rather than an open-market purchase. According to the disclosure, these restricted shares will vest in three equal installments on January 20, 2027, January 20, 2028, and January 20, 2029. Following this grant, Vazzano directly beneficially owns 587,226 shares of Abeona Therapeutics common stock.
Abeona Therapeutics Inc. disclosed an equity grant to its Chief Executive Officer and director, Vishwas Seshadri. On January 20, 2026, he received 365,422 shares of common stock as restricted stock at a price of $0.00 per share. After this award, he beneficially owned 1,530,240 shares of Abeona common stock in total.
The restricted stock will vest in three equal installments, with one-third of the shares scheduled to vest on each of January 20, 2027, January 20, 2028, and January 20, 2029, aligning the CEO’s compensation with the company’s multi‑year performance.
Abeona Therapeutics reported an insider equity award for its SVP and Chief Legal Officer, Brendan M. O'Malley. On January 20, 2026, he received 113,949 shares of common stock as restricted stock at a price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
The restricted stock will vest in three equal installments, with one-third vesting on January 20, 2027, one-third on January 20, 2028, and the final third on January 20, 2029. Following this award, O'Malley beneficially owns 464,712 shares of Abeona Therapeutics common stock, held directly.
Abeona Therapeutics (ABEO) reported Q3 2025 results, reflecting the first months after FDA approval of ZEVASKYN for RDEB. The quarter showed a net loss of $5.2 million, compared with a $30.3 million loss a year ago, as commercialization spending ramped. Year-to-date, the company recorded $91.6 million in net income, largely from a $152.4 million gain on the sale of a Priority Review Voucher.
Liquidity strengthened: cash and cash equivalents were $82.9 million and short‑term investments were $124.2 million as of September 30, 2025. Stockholders’ equity rose to $171.2 million. Q3 operating expenses included R&D $4.2 million and SG&A $19.3 million as the company built out commercial infrastructure and manufacturing capacity. Inventory totaled $4.9 million (raw materials). Warrant liabilities declined to $22.6 million. The company maintained a $20.0 million senior term loan; an amendment on July 18, 2025 reduced the interest rate to a fixed 11.75% and included issuance of 16,473 new warrants. Common shares outstanding were 54,191,361 as of November 7, 2025.
Abeona Therapeutics Inc. (ABEO) furnished quarterly results information. The company reported that it issued a press release regarding its financial results for the quarter ended September 30, 2025, and furnished it under Item 2.02.
The full text of the release is included as Exhibit 99.1. As stated, the information under Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference except as expressly set forth by specific reference.
Abeona Therapeutics (ABEO) CEO and Director Vishwas Seshadri reported a Form 4 transaction. He sold 249 shares of common stock on 10/16/2025 at $5.485 per share, a sale described as to cover tax obligations from the vesting of restricted stock awards.
Following the transaction, he beneficially owns 1,189,818 shares, held directly.
Nantahala Capital Management, LLC and two managers report shared beneficial ownership of 5,184,662 shares of Abeona Therapeutics, representing 9.99% of the outstanding common stock as of 09/30/2025. The total includes 619,997 shares that may be acquired within 60 days upon exercise of warrants. Nantahala reports shared voting and dispositive power over these shares; none are held with sole voting or sole dispositive power. The filing states the holdings are managed in the ordinary course of business and not for the purpose of changing control. Contact and organizational details for Nantahala, and certifications by Nantahala and managers Wilmot B. Harkey and Daniel Mack, are included with signatures dated 10/06/2025.
A Nantahala Capital Partners Schedule 13G filed for ABEONA THERAPEUTICS INC. reports shared beneficial ownership of 5.09% of common stock as of 09/29/2025. Nantahala discloses beneficial ownership of 2,618,462 shares, which includes 179,832 shares exercisable within sixty days. The filing states Nantahala holds no sole voting or dispositive power and reports shared voting and dispositive power for the full amount. The ownership percentage is calculated using a reported outstanding share count of 51,278,539 shares from the issuer's Form 10-Q for the period ended 06/30/2025. Signatures by compliance and management representatives are dated 10/06/2025.